
Embecta Faces Securities Lawsuit Over Insulin Needle Sales Claims
A 57.8% single-day stock collapse has triggered a class action lawsuit against Embecta Corp., with attorneys alleging the medical device manufacturer misled shareholders about the stability of its core insulin pen needle business throughout late 2025 and early 2026.























